Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monte Rosa Therapeutics (GLUE) Total Liabilities: 2023-2024

Historic Total Liabilities for Monte Rosa Therapeutics (GLUE) over the last 2 years, with Dec 2024 value amounting to $215.8 million.

  • Monte Rosa Therapeutics' Total Liabilities rose 95.22% to $214.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $214.0 million, marking a year-over-year increase of 95.22%. This contributed to the annual value of $215.8 million for FY2024, which is 73.32% up from last year.
  • Latest data reveals that Monte Rosa Therapeutics reported Total Liabilities of $215.8 million as of FY2024, which was up 73.32% from $124.5 million recorded in FY2023.
  • Monte Rosa Therapeutics' Total Liabilities' 5-year high stood at $215.8 million during FY2024, with a 5-year trough of $124.5 million in FY2023.
  • Moreover, its 2-year median value for Total Liabilities was $170.2 million (2023), whereas its average is $170.2 million.
  • Data for Monte Rosa Therapeutics' Total Liabilities shows a peak YoY soared of 73.32% (in 2024) over the last 5 years.
  • Yearly analysis of 2 years shows Monte Rosa Therapeutics' Total Liabilities stood at $124.5 million in 2023, then skyrocketed by 73.32% to $215.8 million in 2024.